New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:25 EDTBA, BA, LLY, LLYSenate Judiciary Committee to hold a hearing
The Subcommittee on Crime and Terrorism holds a hearing entitled, "Economic Espionage and Trade Secret Theft: Are Our Laws Adequate for Today’s Threats? with Vice President Paul Hoffman of The Boeing Company and Vice President Doug Norman of Eli Lilly & Company on May 13 at 2:30 pm. Webcast Link
News For BA;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 26, 2015
07:50 EDTLLYEli Lilly price target raised to $92 from $77 at Leerink
Subscribe for More Information
07:34 EDTLLYEli Lilly volatility elevated as shares near record high
Subscribe for More Information
07:26 EDTBASRA International exploring sale or IPO, Reuters reports
Subscribe for More Information
05:17 EDTLLYEli Lilly, Adocia report positive Phase 1b topline results for BioChaperone Lisp
Subscribe for More Information
June 25, 2015
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Buy from Neutral at BofA/Merrill... Eli Lilly (LLY) upgraded to Buy, added to US 1 List at BofA/Merrill... Finish Line (FINL) upgraded to Buy from Neutral at B. Riley... Gran Tierra (GTE) upgraded to Buy from Hold at Canaccord... Greenhill & Co. (GHL) upgraded to Buy from Sell at Goldman... Magnum Hunter (MHR) upgraded to Equalweight from Underweight at Capital One... Marathon Oil (MRO) upgraded to Buy from Neutral at UBS... Newpark Resources (NR) upgraded to Strong Buy from Outperform at Raymond James... Office Depot (ODP) upgraded to Outperform from Market Perform at Telsey Advisory... Quanex (NX) upgraded to Outperform from In-Line at Imperial Capital... Vestas Wind (VWDRY) upgraded to Outperform from Neutral at Exane BNP Paribas... Web.com (WWWW) upgraded to Buy from Neutral at B. Riley... NRG Yield upgraded to Outperform from Market Perform at Avondale.
07:39 EDTLLYEli Lilly upgraded to Buy, added to US 1 List at BofA/Merrill
As previously reported, BofA/Merrill upgraded Eli Lilly to Buy from Neutral and added it to the US 1 List. The firm raised estimates and increased its price target to $101 from $74 based on more bullish pipeline expectations. BofA/Merrill highlights eva and sola pipelines, which have high risk/reward opportunities with Phase III data in the next 12-18 months. Firm forecasts peak sales of $1.5B for eva and $2B for sola and said success in either of these programs would result in significant upside to estimates.
06:44 EDTLLYEli Lilly upgraded to Buy from Neutral at BofA/Merrill
Subscribe for More Information
06:07 EDTLLYEli Lilly reports UK court rules in favor of Lilly in Alimta vitamin patent suit
Eli Lilly announced that the Court of Appeal has ruled that the Alimta vitamin regimen patent would be indirectly infringed by a generic competitor that had stated its intent to market certain alternative salt forms of pemetrexed in the United Kingdom prior to the UK patent's expiration in June 2021. Specifically, the Court of Appeal held that commercialization of these alternative salt forms in the products as proposed would constitute indirect infringement by supplying an essential means for putting the patented invention into effect. The decision came in the case of Actavis v. Eli Lilly and Company. The Court of Appeal also held there was no difference between the law in the UK and that in France, Italy and Spain as it relates to indirect infringement, and so reversed the High Court's decision granting declarations of noninfringement over the Alimta vitamin regimen patents in those countries. Actavis may seek permission to appeal the decision to the UK Supreme Court. In addition, Actavis has stated it may ask the High Court to decide whether a different proposed product would infringe the patent. The Court of Appeal has ruled that the High Court will need to decide whether it will hear this new claim. If the High Court decides to hear Actavis' case on the different proposed product, Lilly will defend the case vigorously. In Europe, the compound patents for Alimta remain in force and are expected to provide exclusivity through December 2015. This decision increases the likelihood that the vitamin regimen patents for Alimta will provide exclusivity in the UK, France, Italy and Spain through June 2021.
05:53 EDTBABoeing CEO Muilenburg prioritizes cost cutting challenges, Financial Times says
Subscribe for More Information
June 24, 2015
16:57 EDTBABoeing to slow 747-8 production to one per month in March, Reuters says
Boeing will slow its production of the 747-8 jumbo jet to 1 per month beginning in March, a decrease of 23%, reports Reuters. The decision to slow production was not related to the company's CEO transition, Reuters added, citing the company. Reference Link
16:21 EDTBAOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:30 EDTBAOn The Fly: Top stock stories at midday
Subscribe for More Information
07:32 EDTBANew Boeing CEO Muilenburg to inherit tough decisions, Bloomberg says
Subscribe for More Information
June 23, 2015
19:03 EDTBAOn The Fly: After Hours Movers
UP AFTER PROVIDING GUIDANCE: MeetMe (MEET), up 18.8%. ALSO HIGHER: Nektar Therapeutics (NKTR), up 4.3% after being added to S&P 600... Quidel (QDEL), up 5% after receiving FDA clearance for new Solana molecular system and assay... Vanda Pharmaceuticals (VNDA), up 4.6% after announcing positive results from REPRIEVE study... Netflix (NFLX), up 3.4% after announcing seven-for-one stock split. LOWER: Alcobra (ADHD), down 2.5% after announcing that it will host a conference call and simultaneous webcast presentation to present results from the Phase II clinical trial of MDX... Sysco (SYY), down 2.6% after bid for U.S. foods blocked was blocked by a federal judge... Boeing (BA), down marginally after announcing CEO transition.
17:40 EDTBABoeing incoming CEO Muilenburg says must deliver on 777 bridge program
Regarding the appointment of Dennis Muilenburg as Boeing CEO, outgoing CEO James McNerney says, "in many ways, there's not going to be a change." Muilenburg noted that the current defense market is more "challenging," and that the company needs to deliver on its 777 bridge program. Muilenburg added that the company's backlog remains "solid." Both executives are speaking on CNBC.
16:32 EDTBABoeing names Dennis Muilenburg CEO
The Boeing board has elected Dennis Muilenburg as the company's CEO, succeeding W. James McNerney, Jr., who held the position for the past 10 years. Muilenburg, who has served as Boeing president and COO since 2013, becomes president and CEO on July 1. McNerney, who joined Boeing's board in 2001, continues as its chairman. To ensure a smooth transition of his CEO responsibilities to Muilenburg, he will continue working as a company employee until retiring at the end of February 2016.
13:15 EDTBABoeing sued over claims of toxic airplane cabin air, Chicago Tribune says
Subscribe for More Information
June 22, 2015
11:31 EDTLLYActinobac Biomed signs licensing agreemnt with Eli Lilly unit Elanco
Subscribe for More Information
08:39 EDTLLYBernstein pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
06:18 EDTBASuppliers worried about Airbus, Boeing production rate hike, Reuters reports
Major engine suppliers, including General Electric (GE) and Safran, are becoming worried that they may lose out if they invest to meet higher commercial jet production targets from Airbus (EADSY) and Boeing (BA) that may prove unsustainable, Reuters reports. Airbus and Boeing have plans to raise production rates of their best selling single aisle planes by 25% to 50-52 a month in 2017-2018, the report says. Suppliers have said that they need to secure the start of a steep rise in output before making a commitment to even loftier targets, the report says. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use